US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Conexeu Sciences Inc.

3.32

-0.2500-7.00%

Volume:95.79K

Turnover:332.06K

Market Cap:93.65M

PE:-6.68

High:3.60

Open:3.51

Low:3.32

Close:3.57

52wk High:18.79

52wk Low:3.32

Shares:28.21M

Float Shares:16.29M

Volume Ratio:0.54

T/O Rate:0.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4970

EPS(LYR):-0.3104

ROE:-332.94%

ROA:-170.73%

PB:16.01

PE(LYR):-10.70

Loading ...

Overview Company News Filings

How Investors Are Reacting To Conexeu Sciences (CNXU) Bolstering Leadership For CXU Device Commercialization

Simply Wall St.

Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences names co-founder David Bogart chief commercial officer

Press Release: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences issues 416,667 shares on warrant exercise for gross proceeds of about $166,667

Conexeu Sciences provides update on manufacturing scale up for wound care device

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

Assessing Conexeu Sciences (CNXU) Valuation After Launch Of Preclinical B.R.E.A.S.T. Program

Simply Wall St.

Conexeu Sciences files Form 3 as Michael G. Wright reports initial beneficial ownership

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:32 AM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/CNXU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","market":"US","secType":"STK","nameCN":"Conexeu Sciences Inc.","latestPrice":3.32,"timestamp":1790884800000,"preClose":3.57,"halted":0,"volume":95785,"delay":0,"changeRate":-0.0700280112044818,"floatShares":16291503,"shares":28206698,"eps":-0.497,"marketStatus":"Pre-Mkt","change":-0.25,"latestTime":"10-02 07:27:53 EDT","open":3.51,"high":3.6,"low":3.32,"amount":332055.12962749996,"amplitude":0.078431,"askPrice":3.71,"askSize":1,"bidPrice":3.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.497,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"listingDate":1779336000000,"exchange":"NASDAQ","adjPreClose":3.32,"postHourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.32,"latestTime":"19:30 EDT","volume":52,"amount":173.293,"timestamp":1790897404862,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5375592787307231},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","floatShares":16291503,"roa":"-170.73%","roe":"-332.94%","lyrEps":-0.310358,"volumeRatio":0.5375592787307231,"shares":28206698,"dividePrice":0,"high":3.6,"amplitude":0.078431,"preClose":3.57,"low":3.32,"week52Low":3.32,"pbRate":"16.01","week52High":18.7915,"institutionHeld":0,"latestPrice":3.32,"committee":0.980198,"eps":-0.497,"divideRate":0,"volume":95785,"delay":0,"ttmEps":-0.497,"open":3.51,"prevYearClose":13.5,"prevWeekClose":3.89,"prevMonthClose":3.57,"prevQuarterClose":3.57,"fiveDayClose":3.96,"twentyDayClose":5.56,"sixtyDayClose":10.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNXU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-14","symbol":"CNXU","fiscalQuarterEnding":"2026/07","expectedEps":-0.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1789358400000,"reportTimeType":"post","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNXU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNXU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1782187200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNXU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNXU","date":"2026-09-30","current":-6.68008,"percent":1,"low":-79.55424,"twenty":-54.946721,"median":-34.012232,"eighty":-20.727486,"high":-7.680148,"avg":-36.86167,"sd":17.625188,"marketCap":104646849},"quantilePoints":[{"date":"2026-05-22","current":-61.707651,"twenty":-61.707651,"median":-61.707651,"eighty":-61.707651,"marketCap":330278847},{"date":"2026-05-29","current":-54.672884,"twenty":-65.607461,"median":-64.327983,"eighty":-60.300698,"marketCap":292626553},{"date":"2026-06-05","current":-75.541118,"twenty":-76.3343,"median":-65.838806,"eighty":-60.437616,"marketCap":404319936},{"date":"2026-06-12","current":-57.26961,"twenty":-72.783868,"median":-65.815199,"eighty":-60.63119,"marketCap":306525051},{"date":"2026-06-18","current":-61.471585,"twenty":-72.022319,"median":-64.327983,"eighty":-56.504756,"marketCap":329015347},{"date":"2026-06-26","current":-37.989619,"twenty":-69.581868,"median":-61.589618,"eighty":-54.125211,"marketCap":273470132},{"date":"2026-07-02","current":-38.138306,"twenty":-67.458218,"median":-61.182094,"eighty":-40.651122,"marketCap":274540465},{"date":"2026-07-10","current":-36.837292,"twenty":-66.325102,"median":-57.26961,"eighty":-39.424451,"marketCap":265175050},{"date":"2026-07-17","current":-39.067602,"twenty":-65.494149,"median":-53.988293,"eighty":-38.257256,"marketCap":281230048},{"date":"2026-07-24","current":-34.012232,"twenty":-64.738738,"median":-41.558115,"eighty":-37.945013,"marketCap":244838719},{"date":"2026-07-31","current":-32.822733,"twenty":-64.002212,"median":-40.591647,"eighty":-36.004643,"marketCap":236276053},{"date":"2026-08-07","current":-31.484547,"twenty":-62.500833,"median":-39.94114,"eighty":-34.153485,"marketCap":226643055},{"date":"2026-08-14","current":-29.625955,"twenty":-61.660438,"median":-39.067602,"eighty":-32.859905,"marketCap":213263890},{"date":"2026-08-21","current":-35.053043,"twenty":-61.471585,"median":-38.101134,"eighty":-33.023461,"marketCap":252331051},{"date":"2026-08-28","current":-26.168974,"twenty":-61.355789,"median":-37.989619,"eighty":-31.008748,"marketCap":188378643},{"date":"2026-09-04","current":-19.589559,"twenty":-60.536268,"median":-36.985979,"eighty":-29.090681,"marketCap":141016399},{"date":"2026-09-11","current":-15.798031,"twenty":-59.110925,"median":-36.446988,"eighty":-28.547972,"marketCap":113722902},{"date":"2026-09-18","current":-20.767449,"twenty":-57.26961,"median":-35.313246,"eighty":-27.023926,"marketCap":149495499},{"date":"2026-09-25","current":-8.197678,"twenty":-55.357476,"median":-34.88577,"eighty":-25.927357,"marketCap":111698524},{"date":"2026-09-30","current":-7.680148,"twenty":-54.946721,"median":-34.012232,"eighty":-20.727486,"marketCap":104646849}],"updateTime":1790915790983},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNXU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644707093","title":"How Investors Are Reacting To Conexeu Sciences (CNXU) Bolstering Leadership For CXU Device Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2644707093","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644707093?lang=en_us&edition=fundamental","pubTime":"2026-06-18 17:37","pubTimestamp":1781775422,"startTime":"0","endTime":"0","summary":"Earlier in June 2026, Conexeu Sciences Inc. expanded its leadership bench by adding three seasoned directors, appointing co-founder David Bogart as Chief Commercial Officer, and bringing aesthetics expert Melinda Farina onto its advisory board, while also updating key board committees.\nThese changes, paired with recent progress on scaling manufacturing and regulatory preparation for its CXU wound care device, highlight Conexeu’s push to turn its regenerative tissue platform into a commercial...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/how-investors-are-reacting-to-conexeu-sciences-cnxu-bolsteri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/how-investors-are-reacting-to-conexeu-sciences-cnxu-bolsteri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNXU","BK4139","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643523297","title":"Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2643523297","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643523297?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:15","pubTimestamp":1781612100,"startTime":"0","endTime":"0","summary":"A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization -- in one of medicine's most consequential frontiers.The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine -- helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209908","title":"BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209908","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643209908?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:47","pubTimestamp":1781531243,"startTime":"0","endTime":"0","summary":"BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq ListingJune 15 (Reuters) - Conexeu Sciences Inc CNXU.O:CONEXEU EXPANDS BOARD, EXECUTIVE, AND ADVISORY","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA88PTH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643120535","title":"Conexeu Sciences names co-founder David Bogart chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643120535","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643120535?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:31","pubTimestamp":1781526668,"startTime":"0","endTime":"0","summary":"Conexeu named co-founder David Bogart as chief commercial officer, tasking him with commercialization and strategic operations.Bogart is a capital markets adviser and investor-relations strategist who has worked on more than $75 million in capital formation.Three directors joined the board: Kyowa Kirin North America CFO Ana Bastiani-Posner, Lucid Hearing CFO April Burke, RX3 Growth Partners co-managing partner Andrew Costa.Costa previously held investment banking roles at Morgan Stanley, J.P. Morgan; earlier served as a U.S. Air Force captain.Melinda Farina joined the advisory board; she founded Integrated Aesthetics Consulting and Beauty Brokers, advising physicians and aesthetic brands.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLbLVFKp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU0098860793.USD","LU0820561909.HKD","LU0267386448.USD","LU0158827781.USD","LU2133065610.SGD","LU1116320901.HKD","IE00BJTD4V19.USD","LU1244550577.SGD","IE00BYXW3230.USD","IE0034235188.USD","IE00BZ1G4Q59.USD","IE00BKDWB100.SGD","LU0070302665.USD","NDAQ","LU0238689110.USD","JPX","LU1791710400.SGD","LU1732799900.SGD","LU0211327993.USD","LU0158827948.USD","LU0976567544.SGD","LU0106261372.USD","BK4588","IE00BLSP4452.SGD","JPMO","LU2237443978.SGD","BK4516","LU2237443549.SGD","LU1496350502.SGD","BK4127","IE00BN0W2T93.GBP","LU2111349929.HKD","LU0795875169.SGD","LU0211331839.USD","LU0208291251.USD","CNXU","LU0215105999.USD","IE00BDCRKT87.USD","JPO","LU1084165304.USD","LU2237443895.HKD","BK4139","LU2023250504.SGD","SG9999014013.SGD","LU0149725797.USD","LU1791710582.SGD","IE000M9KFDE8.USD","LU1720051017.SGD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643920307","title":"Press Release: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643920307","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643920307?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526600,"startTime":"0","endTime":"0","summary":"RENO, Nev., June 15, 2026  -- Conexeu Sciences Inc.  , a biotechnology company advancing tissue regeneration, today announced additions to its leadership team, effective immediately.Conexeu has appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to its Board of Directors. The appointments add significant experience across healthcare, finance, capital markets, operations, and strategic growth initiatives as Conexeu continues advancing its proprietary CXU platform, and long-term commercialization strategy.The Company also announced the appointment of Co-Founder and Director David Bogart as Chief Commercial Officer. Bogart will lead commercialization efforts and strategic operational initiatives, having helped shape Conexeu's platform and regulatory strategy from inception. He has foundational knowledge of the intellectual property and multi-indication pathway to expand Conexeu's presence within the regenerative medicine sector.Additionally, Melinda Farina, the founder of Integra","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["POST","TM","BK4585","BK4588","BK4139","BK4604","03160","BK4555","BK4212","CNXU","BK4099","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642849716","title":"Conexeu Sciences issues 416,667 shares on warrant exercise for gross proceeds of about $166,667","url":"https://stock-news.laohu8.com/highlight/detail?id=2642849716","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642849716?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:31","pubTimestamp":1781037103,"startTime":"0","endTime":"0","summary":"Conexeu Sciences issued 416,667 common shares on June 4 from warrant exercises, raising about $166,667 for working capital.Issued 416,667 transferable incentive warrants to the exercising holder; each is exercisable for 36 months at $2.3 per share.Issued 100,000 common shares on June 8 from performance warrant exercises at $0.001 per share, raising $100.Common shares outstanding rose to 26,758,330; 410,338 program warrants remained outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL2NLHYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641848282","title":"Conexeu Sciences provides update on manufacturing scale up for wound care device","url":"https://stock-news.laohu8.com/highlight/detail?id=2641848282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641848282?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:01","pubTimestamp":1780923673,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) announced progress in manufacturing scale up and standardized formulation methods with its contract development and manufac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conexeu-sciences-provides-update-on-manufacturing-scale-up-for-wound-care-device-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conexeu-sciences-provides-update-on-manufacturing-scale-up-for-wound-care-device-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484515","title":"Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484515","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484515?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:30","pubTimestamp":1780921800,"startTime":"0","endTime":"0","summary":"Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510 premarket notification submission. Ten Minute Tissue with CXU: a thermo-sensitive extracellular matrix  designed to remain fluid at room temperature for conformability and seamless application.Ten Minute Tissue with CXU; a thermo-sensitive extracellular matrix , designed to gel in situ at body temperature in approximately ten minutes, for stabilized integration.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308103/0/en/Conexeu-Sciences-Reports-Manufacturing-Scale-Up-and-Regulatory-Progress-for-Lead-CXU-Wound-Care-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","CNXU","BK4588","LABU","BK4139","BK4585","BK4097","LU2065732104.USD","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904697","title":"Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904697","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904697?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:30","pubTimestamp":1780489800,"startTime":"0","endTime":"0","summary":"RENO, Nev., June  03, 2026  (GLOBE NEWSWIRE) -- Conexeu Sciences Inc.(Nasdaq: CNXU) (\"Conexeu\" or the \"Company\"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Be","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306034/0/en/Conexeu-Sciences-to-Ring-Nasdaq-Bell-on-June-10-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REI","CNXU","BK4213","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995058","title":"Assessing Conexeu Sciences (CNXU) Valuation After Launch Of Preclinical B.R.E.A.S.T. Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995058","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995058?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:29","pubTimestamp":1780360190,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) has drawn fresh attention after launching a preclinical development program for its 3D printed B.R.E.A.S.T. bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine.\nSee our latest analysis for Conexeu Sciences.\nThe recent preclinical program launch and the stock’s addition to the Nasdaq Composite Index have coincided with a 1 day share price return of 20.43% to US$14.12. However, the year to date share price return of 8.03% and a 7 day...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/assessing-conexeu-sciences-cnxu-valuation-after-launch-of-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/assessing-conexeu-sciences-cnxu-valuation-after-launch-of-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638680437","title":"Conexeu Sciences files Form 3 as Michael G. Wright reports initial beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2638680437","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638680437?lang=en_us&edition=fundamental","pubTime":"2026-05-28 02:06","pubTimestamp":1779905187,"startTime":"0","endTime":"0","summary":"Conexeu Sciences initial Form 3 filed for Michael G. Wright as a 10% owner, triggered by an event dated May 11, 2026.Reported beneficial ownership of 750,000 common shares held directly.Disclosed 1.5 million common shares held indirectly through N3GU Investments LLC.Reported derivative holdings include options for 50,000 shares at USD 0.4, exercisable since June 9, 2025, expiring June 9, 2030.Indirect warrants include 78,595 shares at USD 0.8 expiring Jan. 21, 2027, plus performance warrants for 900,000 shares at USD 0.001 expiring June 5, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5tzlCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638933689","title":"UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2638933689","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638933689?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:36","pubTimestamp":1779892560,"startTime":"0","endTime":"0","summary":"The Integrated Tissue-Organ Printer  system . ITOP was used to print Conexeu Sciences' B.R.E.A.S.T.BioRegenerative Ergonomically Architected Smart Tissue , developed by Conexeu Sciences, Inc. and printed with support from the RegenMed Development Organization  at the Wake Forest Institute for Regenerative Medicine . The work reflects ReMDO's ongoing support of Conexeu Sciences' efforts to translate regenerative medicine technologies into clinical practice.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3302164/0/en/UPDATE-Conexeu-Sciences-Initiates-Preclinical-Development-Program-for-B-R-E-A-S-T-Bioregenerative-Matrix-Platform-with-Wake-Forest-Institute-for-Regenerative-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637944332","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:32 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2637944332","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637944332?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:32","pubTimestamp":1779373948,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:32 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nAQN2M01AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":33,"code":"91000000","status":"200"}]}}